Venous thromboembolism (VTE) is a potentially fatal cardiovascular condition characterized by the development of a thrombus in the vasculature. Treatment options for VTE have been largely limited…
As the Relapsed/Refractory Treatment Setting for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Becomes More Crowded, What Key Attributes Will Differentiate Emerging Therapies According to…
The lackluster global antibiotics pipeline and surge of antibiotic resistance in clinical isolates in China have triggered a new quest for novel antibiotics against complicated HTI. Many local and…
By February 2014, European marketing authorizations were granted for three new disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS)—Aubagio (Sanofi/Genzyme), Lemtrada (…
As the Relapsed/Refractory Treatment Setting for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Becomes More Crowded, What Key Attributes Will Differentiate Emerging Therapies According to…
The biosimilars market is not all about the United States, Europe, and Japan. Although these developed markets account for 80% of branded biologics sales, the rest-of-world segment includes many…
Myelodysplastic syndromes (MDS) consists of a group of disorders that are heterogeneous in cause and manifestations but share the common features of aberrant hematopoiesis and deteriorating…
This quarterly report provides a detailed analysis of emerging and current therapies in nephrology based on responses from surveyed U.S. nephrologists. Emphasis is on anemia management (ESAs and IV…
Hypertriglyceridemia (HTG) is defined as an abnormal concentration of triglyceride in the blood. Classification of serum triglyceride (TG) levels greater than 150 mg/dL as elevated is largely based…
In order to maximize potential commercial return, biosimilar developers must adopt clear and effective strategies that leverage their internal capability and potentially capture the expertise of…
In the Highly Genericized Insomnia Market, What Opportunities Remain for New Therapies? We expect the prevalence of insomnia in the seven major pharmaceutical markets under study (United States,…
In the Highly Genericized Insomnia Market, What Opportunities Remain for New Therapies? We expect the prevalence of insomnia in the seven major pharmaceutical markets under study (United States,…
In The Crowded MRSA cSSSI Market, How Will Emerging Therapies Differentiate Themselves from Current Standard of Care? Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important…
In The Crowded MRSA cSSSI Market, How Will Emerging Therapies Differentiate Themselves from Current Standard of Care? Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important…
What Untapped Opportunities Remain for the Treatment of Genotype-3 Infections? Affecting at least 170 million people worldwide, chronic hepatitis C virus (HCV) is a serious public health crisis…